


## Ezetimibe-d<sub>4</sub>-1

<b>Cat. No.:</b>	HY-17376S1		
<b>CAS No.:</b>	1093659-89-2		
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>17</sub> D <sub>4</sub> F <sub>2</sub> NO <sub>3</sub>		
<b>Molecular Weight:</b>	413.45		
<b>Target:</b>	Keap1-Nrf2; Autophagy		
<b>Pathway:</b>	NF-κB; Autophagy		
<b>Storage:</b>	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

#### Description

Ezetimibe-d<sub>4</sub>-1 is deuterium labeled Ezetimibe. Ezetimibe (SCH 58235) is a potent cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator.

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Chang E, et al. Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats. *World J Gastroenterol.* 2015 Jul 7;21(25):7754-63.
- [3]. Lee DH, et al. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. *Free Radic Biol Med.* 2016 Sep 12;99:520-532.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA